New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
06:42 EDTTEVA, HLFStocks with implied volatility movement; TEVA HLF
Stocks with implied volatility movement; Teva (TEVA) 28, Herbalife (HLF) 81 according to iVolatility.
News For TEVA;HLF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 20, 2014
06:28 EDTTEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
05:54 EDTHLFStocks with implied volatility movement; HLD SD
Stocks with implied volatility movement; Herbalife (HLF) 109, SandRidge Energy (SD) 97 according to iVolatility.
October 14, 2014
11:23 EDTTEVABIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:19 EDTTEVATeva upgraded to Buy from Hold at Standpoint Research
October 13, 2014
09:01 EDTHLFHerbalife moving distributor websites to central control, NY Post reports
Subscribe for More Information
October 10, 2014
12:11 EDTHLFOptions with increasing implied volatility
Subscribe for More Information
10:55 EDTHLFHerbalife volatility increases
Subscribe for More Information
October 9, 2014
16:11 EDTTEVAAlexza reports 32,278 Adasuve units shipped to Teva in Q3
Subscribe for More Information
14:32 EDTHLFIcahn says never discussed Netflix with Tim Cook
Subscribe for More Information
October 8, 2014
08:05 EDTTEVATeva initiates NDA submission to FDA for CEP-33237
Teva Pharmaceutical announced the initiation of a rolling New Drug Application submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Tevaís proprietary technology providing potential abuse-deterrent properties CEP-33237 as allowed for fast track designated products. Teva expects to complete the NDA submission by the end of 2014. Teva also announced positive results from a nasal Human Abuse Liability study which supports the NDA. The nasal HAL study found that in nondependent, recreational opioid users, abuse potential for crushed intranasal CEP-33237 was significantly lower than intranasal immediate-release hydrocodone. Teva has now completed positive HAL studies in the two most common routes of hydrocodone abuse, oral and intranasal. CEP-33237 demonstrated a safety profile in the Phase III study that is consistent with the known safety profile of hydrocodone and other opioid analgesic therapies. Adverse events reported in 5% or more of hydrocodone-treated patients during either the titration or double-blind treatment periods included nausea, constipation, vomiting, headache, somnolence and dizziness.
06:47 EDTTEVALawmakers may push for new regulations on generic drug makers, NY Times says
After the prices of some generic drugs soared more than 1,000% over the last year, two influential members of Congress are probing the sector and threatening to look to impose new regulations on it, according to The New York Times. Generic drug makers include Teva (TEVA), Mylan (MYL), Actavis (ACT), and Lannett (LCI).Reference Link
October 7, 2014
14:39 EDTHLFFTC probe of Herbalife seen lasting 'well into' next year, NY Post reporter says
Subscribe for More Information
14:19 EDTHLFHerbalife expects discipline, but not shutdown, following FTC probe, FBN says
Subscribe for More Information
13:59 EDTHLFHerbalife expects some discipline, not shutdown, from FTC, Gasparino says
Subscribe for More Information
06:13 EDTHLFHerbalife names ex-FTC commissioner to lead compliance group
Herbalife yesterday announced the appointment of Pamela Jones Harbour to the newly created role of SVP, global member compliance and privacy, reporting to Mark Friedman, EVP and general counsel. Harbour will develop and enhance policies and infrastructure that ensure effective education, training and mentoring programs for the nearly 4 million independent Herbalife members worldwide, underpinned by robust and consistent monitoring and enforcement procedures. In addition to her compliance responsibilities, Harbour will also coordinate the companyís global privacy and cyber security efforts. Harbour served as a Commissioner at the Federal Trade Commission from 2003-2010 and a prosecutor at the New York State Attorney Generalís office for 12 years.
October 6, 2014
14:53 EDTHLFHerbalife, Nu Skin jump to session highs
Subscribe for More Information
11:58 EDTTEVATeva simplifaction plans expected but positive, says BMO Capital
Subscribe for More Information
08:32 EDTTEVATeva identifies 14 pipeline projects for discontinuation or divestment
Subscribe for More Information
08:32 EDTTEVATeva announces results of strategic review of core specialty therapeutic areas
Subscribe for More Information
06:44 EDTHLFHerbalife names ex-regulator to lead compliance group, Reuters says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use